Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis

New England Journal of Medicine

Volumn 333, Issue 22, 1995, Pages 1437-1444

  Liberman, Uri A ^a   Weiss, Stuart R ^a   Bröll, Johann ^a   Minne, Helmut W ^a   Quan, Hui ^a   Bell, Norman H ^a   Rodriguez Portales, Jose ^a   Downs, Robert W ^a   Dequeker, Jan ^a   Favus, Murray ^a   Seeman, Ego ^a   Recker, Robert R ^a   Capizzi, Thomas ^a   Santora, Arthur C ^a   Lombardi, Antonio ^a   Shah, Raksha V ^a   Hirsch, Laurence J ^a   Karpf, David B ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; CALCIUM; PLACEBO;

ABSORPTIOMETRY; ADULT; AGED; ARTICLE; BONE DENSITY; BONE MINERAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; FRACTURE; GASTROINTESTINAL SYMPTOM; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MUSCULOSKELETAL DISEASE; ORAL DRUG ADMINISTRATION; OSTEOPOROSIS; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SPINE MALFORMATION; VERTEBRA FRACTURE;

AGED; AGED, 80 AND OVER; ALENDRONATE; BODY HEIGHT; BONE DENSITY; CALCIUM CARBONATE; DIPHOSPHONATES; DOUBLE-BLIND METHOD; FEMALE; FRACTURES, BONE; HUMANS; INCIDENCE; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; SPINAL FRACTURES; SPINE;

EID: 0028851590     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJM199511303332201     Document Type: Article

References (32)

1. Riggs BL, Melton LJ III The prevention and treatment of osteoporosis. N Engl J Med 1992; 327: 620-627
2. Consensus development conference: diagnosis, prophylaxis, and treatment of osteoporosis. Am J Med 1993; 94: 646-650
3. Burger H, van Daele PLA, Algra D, Vertebral deformities as predictors of non-vertebral fractures. BMJ 1994; 309: 991-992
4. Leichter I, Margulies JY, Weinreb A, The relationship between bone density, mineral content, and mechanical strength in the femoral neck. Clin Orthop 1982; 163: 272-281
5. Fleisch H Bisphosphonates: pharmacology and use in the treatment of tumor-induced hypercalcaemic and metastatic bone disease. Drugs 1991; 42: 919-944
6. Schenk R, Eggli P, Fleisch H, Rosini S Quantitative morphometric evaluation of the inhibitory activity of new aminobisphosphonates on bone resorption in the rat. Calcif Tissue Int 1986; 38: 342-349
7. Shinoda H, Adamek G, Felix R, Fleisch H, Schenk R, Hagan P Structure-activity relationships of various bisphosphonates. Calcif Tissue Int 1983; 35: 87-99
8. Marcus R Cyclic etidronate: has the rose lost its bloom? Am J Med 1993; 95: 555-556
9. Axelrod DW, Teitelbaum SL Results of long-term cyclical etidronate therapy: bone histomorphometry and clinical correlates. J Bone Miner Res 1994; 9: Suppl 1: S136-S136 abstract.
10. Garnero P, Shih WJ, Gineyts E, Karpf DB, Delmas PD Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment. J Clin Endocrinol Metab 1994; 79: 1693-1700
11. Guy JA, Shea M, Peter CP, Morrissey R, Hayes WC Continuous alendronate treatment throughout growth, maturation, and aging in the rat results in increases in bone mass and mechanical properties. Calcif Tissue Int 1993; 53: 283-288
12. Balena R, Toolan BC, Shea M, The effects of 2-year treatment with the aminobisphosphonate alendronate on bone metabolism, bone histomorphometry, and bone strength in ovariectomized nonhuman primates. J Clin Invest 1993; 92: 2577-2586
13. Arlot MC, Meunier PJ, Chavassieux P, Effects of long-term alendronate treatment for postmenopausal osteoporosis on bone histomorphometry. J Bone Miner Res 1995; 10: Suppl 1: S199-S199 abstract.
14. Ross PD, Davis JW, Epstein RS, Wasnich RD Pre-existing fractures and bone mass predict vertebral fracture incidence in women. Ann Intern Med 1991; 114: 919-923
15. Melton LJ III, Atkinson EJ, O'Fallon WM, Wahner HW, Riggs BL Long-term fracture prediction by bone mineral assessed at different skeletal sites. J Bone Miner Res 1993; 8: 1227-1233
16. Chesnut CH III, McClung MR, Ensrud KE, Alendronate treatment of the postmenopausal osteoporotic woman: effect of multiple dosages on bone mass and bone remodeling. Am J Med 1995; 99: 144-152
17. Melton LJ III, Lane AW, Cooper C, Eastell R, O'Fallon WM, Riggs BL Prevalence and incidence of vertebral deformities. Osteoporos Int 1993; 3: 113-119
18. Minne HW, Leidig G, Wuster C, A newly developed spine deformity index (SDI) to quantitate vertebral crush fractures in patients with osteoporosis. Bone Miner 1988; 3: 335-349
19. Gornbein JA, Lazaro CG, Little RJA Incomplete data in repeated measures analysis. Stat Methods Med Res 1992; 1: 275-295
20. Lufkin EG, Argueta R, Whitaker MD, Pamidronate: an unrecognized problem in gastrointestinal tolerability. Osteoporos Int 1994; 4: 320-322
21. Schiller JH, Rasmussen P, Benson AB III, Maintenance etidronate in the prevention of malignancy-associated hypercalcemia. Arch Intern Med 1987; 147: 963-966
22. Lufkin EG, Wahner HW, O'Fallon WM, Treatment of postmenopausal osteoporosis with transdermal estrogen. Ann Intern Med 1992; 117: 1-9
23. Riggs BL, Hodgson SF, O'Fallon WM, Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis. N Engl J Med 1990; 322: 802-809
24. Kleerekoper M, Peterson EL, Nelson DA, A randomized trial of sodium fluoride as a treatment for postmenopausal osteoporosis. Osteoporos Int 1991; 1: 155-161
25. Pak CYC, Sakhaee K, Piziak V, Slow-release sodium fluoride in the management of postmenopausal osteoporosis: a randomized controlled trial. Ann Intern Med 1994; 120: 625-632
26. Mamelle N, Meunier PJ, Dusan R, Risk-benefit ratio of sodium fluoride treatment in primary vertebral osteoporosis. Lancet 1988; 2: 361-365
27. Watts NB, Harris ST, Genant HK, Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. N Engl J Med 1990; 323: 73-79
28. Storm T, Thamsborg G, Steiniche T, Genant HK, Sorensen OH Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. N Engl J Med 1990; 322: 1265-1271
29. Tilyard MW, Spears GFS, Thomson J, Dovey S Treatment of postmenopausal osteoporosis with calcitriol or calcium. N Engl J Med 1992; 326: 357-362
30. Chapuy MC, Arlot ME, Duboeuf F, Vitamin D3 and calcium to prevent hip fractures in elderly women. N Engl J Med 1992; 327: 1637-1642
31. Overgaard K, Hansen MA, Jensen SB, Christiansen C Effect of salcatonin given intranasally on bone mass and fracture rates in established osteoporosis: a dose-response study. BMJ 1992; 305: 556-561
32. Windeler J, Lange S Events per person year -- a dubious concept. BMJ 1995; 310: 454-456